drugset / Trial / NCT05178901
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
Phase 1
Completed
60 enrolled
Public Health Vaccines LLC
Coalition for Epidemic Preparedness Innovations · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
Timeline
- Start
- 2022-01-10
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PHV02 | Vaccine | 200000 unknown | Intramuscular |
| Subject | PHV02 | Vaccine | 2e+06 unknown | Intramuscular |
| Subject | PHV02 | Vaccine | 2e+07 unknown | Intramuscular |
| Subject | PHV02 | Vaccine | 5e+08 unknown | Intramuscular |